Xdemvy Sets a New Standard in Demodex Blepharitis Care with FDA Nod
XTalks
AUGUST 9, 2023
This new medicine is a positive step forward for the treatment of this disease in many patients who have been struggling for years,” said Christopher Starr, MD, associate professor of ophthalmology at Weill Cornell Medicine, New York Presbyterian Hospital, in the company’s press release. California-based Tarsus Pharmaceuticals Inc.,
Let's personalize your content